Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial

Jane Achan, James K Tibenderana, Daniel Kyabayinze, Fred Wabwire Mangen, Moses R Kamya, Grant Dorsey, Umberto D'Alessandro, Philip J Rosenthal, Ambrose O Talisuna, Jane Achan, James K Tibenderana, Daniel Kyabayinze, Fred Wabwire Mangen, Moses R Kamya, Grant Dorsey, Umberto D'Alessandro, Philip J Rosenthal, Ambrose O Talisuna

Abstract

Objective: To compare the effectiveness of oral quinine with that of artemether-lumefantrine in treating uncomplicated malaria in children.

Design: Randomised, open label effectiveness study.

Setting: Outpatient clinic of Uganda's national referral hospital in Kampala.

Participants: 175 children aged 6 to 59 months with uncomplicated malaria.

Interventions: Participants were randomised to receive oral quinine or artemether-lumefantrine administered by care givers at home.

Main outcome measures: Primary outcomes were parasitological cure rates after 28 days of follow-up unadjusted and adjusted by genotyping to distinguish recrudescence from new infections. Secondary outcomes were adherence to study drug, presence of gametocytes, recovery of haemoglobin concentration from baseline at day 28, and safety profiles.

Results: Using survival analysis the cure rate unadjusted by genotyping was 96% for the artemether-lumefantrine group compared with 64% for the quinine group (hazard ratio 10.7, 95% confidence interval 3.3 to 35.5, P=0.001). In the quinine group 69% (18/26) of parasitological failures were due to recrudescence compared with none in the artemether-lumefantrine group. The mean adherence to artemether-lumefantrine was 94.5% compared with 85.4% to quinine (P=0.0008). Having adherence levels of 80% or more was associated with a decreased risk of treatment failure (0.44, 0.19 to 1.02, P=0.06). Adverse events did not differ between the two groups.

Conclusions: The effectiveness of a seven day course of quinine for the treatment of uncomplicated malaria in Ugandan children was significantly lower than that of artemether-lumefantrine. These findings question the advisability of the recommendation for quinine therapy for uncomplicated malaria in Africa.

Trial registration: ClinicalTrials.gov NCT00540202.

Conflict of interest statement

Competing interests: None declared.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4787392/bin/achj630012.f1_default.jpg
Fig 1 Trial profile
https://www.ncbi.nlm.nih.gov/pmc/articles/instance/4787392/bin/achj630012.f2_default.jpg
Fig 2 Kaplan-Meier curves for risk of treatment failure with oral quinine and artemether-lumefantrine in Ugandan children with uncomplicated malaria

References

    1. World Health Organization. Antimalarial drug combination therapy. Report of WHO technical consultation. WHO/CDS/RBM/2001.35. Geneva: WHO, 2001.
    1. Meshnick SR, Dobson MJ. The history of antimalarial drugs. Antimalarial chemotherapy: mechanisms of action, resistance, and new directions in drug discovery. In: Rosenthal PJ, ed. Totowa, NJ: Humana Press, 2001:15-25.
    1. World Health Organization. WHO guidelines for the treatment of malaria. WHO/HTM/MAL/2006.Geneva: WHO, 2006:1108.
    1. World Health Organization.Global antimalarial drug policies database—AFRO. Antimalarial treatment policies for P falciparum and P vivax by country in WHO Africa region. (accessed 9 Sep 2008).
    1. Zurovac D, Tibenderana JK, Nankabirwa J, Ssekitooleko J, Njogu NJ, Rwakimari JB, et al. Malaria case-management under artemether-lumefantrine treatment policy in Uganda. Malar J 2008;7:181.
    1. Kofoed PE, Ursing J, Rodrigues A, Rombo L. Failures following initial treatment for uncomplicated malaria: quinine as second line therapy. J Pediatr Infect Dis 2007;2:121-6.
    1. Adam I, Salih I, Elbashir MI. Quinine for the treatment of uncomplicated Plasmodium falciparum malaria in eastern Sudan. Trans R Soc Trop Med Hyg 2005;99:736-8.
    1. Pukrittayakamee S, Chantra A, Vanijanonta S, Clemens R, Looareesuwan S, White NJ. Therapeutic responses to quinine and clindamycin in multidrug-resistant falciparum malaria. Antimicrob Agents Chemother 2000;44:2395-8.
    1. McGready R, Ashley EA, Moo E, Cho T, Barends M, Hutagalung R, et al. A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. J Infect Dis 2005;192:846-53.
    1. Adegnika AA, Breitling LP, Agnandji ST, Chai SK, Schutte D, Oyakhirome S, et al. Effectiveness of quinine monotherapy for the treatment of plasmodium falciparum malaria in pregnant women in Lambarene, Gabon. Am J Trop Med Hyg 2005;73:263-6.
    1. Roche J, Guerra-Neira A, Raso J, Benito A. Surveillance of in vivo resistance of Plasmodium falciparum to antimalarial drugs from 1992 to 1999 in Malabo (Equatorial Guinea). Am J Trop Med Hyg 2003;68:598-601.
    1. Ache A, Escorihuela M, Vivas E, Paez E, Miranda L, Matos A, et al. In vivo drug resistance of falciparum malaria in mining areas of Venezuela. Trop Med Int Health 2002;7:737-43.
    1. Parola P, Ranque S, Badiaga S, Niang M, Blin O, Charbit JJ, et al. Controlled trial of 3-day quinine-clindamycin treatment versus 7-day quinine treatment for adult travellers with uncomplicated falciparum malaria imported from the tropics. Antimicrob Agents Chemother 2001;45:932-5.
    1. Quashie NB, Duah NO, Abuaku B, Koram KA. The in-vitro susceptibilities of Ghanaian Plasmodium falciparum to antimalarial drugs. Ann Trop Med Parasitol 2007;101:391-8.
    1. Menard D, Yapou F, Manirakiza A, Djalle D, Matsika-Claquin MD, Talarmin A. Polymorphisms in pfcrt, pfmdr1, dhfr genes and in vitro responses to antimalarials in plasmodium falciparum isolates from Bangui, Central African Republic. Am J Trop Med Hyg 2006;75:381-7.
    1. Henry M, Diallo I, Bordes J, Ka S, Pradines B, Diatta B, et al. Urban malaria in Dakar, Senegal: chemosusceptibility and genetic diversity of plasmodium falciparum isolates. Am J Trop Med Hyg 2006;75:146-51.
    1. Pradines B, Hovette P, Fusai T, Atanda HL, Baret E, Cheval P, et al. Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. J Clin Microbiol 2006;44:2404-8.
    1. Agnamey P, Brasseur P, Eldin de Pecoulas P, Vaillant M, Olliaro P. Plasmodium falciparum in vitro susceptibility to antimalarial drugs in Casamance (south western Senegal) during the first 5 years of routine use of artesunate-amodiaquine. Antimicrob Agents Chemother 2006;50:1531-4.
    1. Tinto H, Rwagacondo C, Karema C, Mupfasoni D, Vandoren W, Rusanganwa E, et al. In-vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, dihydroartemisinin and quinine in an area of high chloroquine resistance in Rwanda. Trans R Soc Trop Med Hyg 2006;100:509-14.
    1. Pukrittayakamee S, Wanwimolruk S, Stepniewska K, Jantra A, Huyakorn S, Looareesuwan S et al. Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated falciparum malaria. Antimicrob Agents Chemother 2003;47:3458-63.
    1. Fungladda W, Honrado ER, Thimasarn K, Kitayaporn D, Karbwang J, Kamolratanakul P, et al. Compliance with artesunate and quinine + tetracycline treatment of uncomplicated falciparum malaria in Thailand. Bull World Health Organ 1998;76(suppl 1):59-66.
    1. Taylor WRJ, White NJ. Antimalarial drug toxicity: a review. Drug Saf 2004;27:25-61.
    1. World Health Organization. Severe falciparum malaria. Trans R Soc Trop Med Hyg 2000;94:1-90.
    1. World Health Organization. WHO toxicity grading scale for determining the severity of adverse events. Geneva: WHO. (accessed 10 Apr 2007).
    1. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am J Trop Med Hyg 1995;52:565-8.
    1. Greenhouse B, Myrick A, Dokomajilar C, Woo JM, Carlson EJ, Rosenthal PJ, et al. Validation of microsatellite markers for use in genotyping polyclonal plasmodium falciparum infections. Am J Trop Med Hyg 2006;75:836-42.
    1. World Health Organization. The use of antimalarial drugs—report of a WHO informal consultation. WHO/CDS/RBM/2001.33. Geneva: WHO, 2000.
    1. Fogg C, Bajunirwe F, Piola P, Biraro S, Checchi F, Kiguli J, et al. Adherence to a six-dose regimen of artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Uganda. Am J Trop Med Hyg 2004;71:525-30.
    1. Mayxay M, Barends M, Brockman A, Jaidee A, Nair S, Sudimack D, et al. In vitro antimalarial drug susceptibility and pfcrt mutation among fresh plasmodium falciparum isolates from the Lao PDR (Laos). Am J Trop Med Hyg 2007;76:245-50.
    1. Chaijaroenkul W, Bangchang KN, Mungthin M, Ward SA. In vitro antimalarial drug susceptibility in Thai border areas from 1998-2003. Malar J 2005;4:37.
    1. Legrand E, Volney B, Meynard B, Mercereau-Puijalon O, Esterre P. In vitro monitoring of Plasmodium falciparum drug resistance in French Guiana: a synopsis of continuous assessment from 1994 to 2005. Antimicrob Agents Chemother 2008;52:288-98.
    1. Kofoed PE, Mapaba E, Lopes F, Pussick F, Aaby P, Rombo L. Comparison of 3, 5 and 7 days’ treatment with Quinimax for falciparum malaria in Guinea-Bissau. Trans R Soc Trop Med Hyg 1997;91:462-4.
    1. Piola P, Fogg C, Bajunirwe F, Biraro S, Grandesso F, Ruzagira E, et al. Supervised versus unsupervised intake of six-dose artemether-lumefantrine for treatment of acute, uncomplicated Plasmodium falciparum malaria in Mbarara, Uganda: a randomised trial. Lancet 2005;365:1467-73.
    1. Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, et al. Amodiaquine alone, amodiaquine+sulfadoxinepyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005;365:1474-80.
    1. Depoortere E, Guthmann JP, Sipilanyambe N, Nkandu E, Fermon F, Balkan S, et al Adherence to the combination of sulphadoxine-pyrimethamine and artesunate in the Maheba refugee settlement, Zambia. Trop Med Int Health 2004;9:62-7.
    1. Oyakhirome S, Pötschke M, Schwarz NG, Dörnemann J, Laengin M, Salazar CO, et al. Artesunate-amodiaquine combination therapy for falciparum malaria in young Gabonese children. Malar J 2007;6:29.
    1. Depoortere E, Guthmann JP, Presse J, Sipilanyambe N, Nkandu E, Balkan S, et al. Efficacy and effectiveness of the combination of sulfadoxine/pyrimethamine and a 3-day course of artesunate for the treatment of uncomplicated falciparum malaria in a refugee settlement in Zambia. Trop Med Int Health 2005;10:139-45.

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit